错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

The parkin V380L variant is a genetic modifier of Machado–Joseph disease with impact on mitophagy

  • Jonasz J. Weber,
  • Leah Czisch,
  • Priscila Pereira Sena,
  • Florian Fath,
  • Chrisovalantou Huridou,
  • Natasa Schwarz,
  • Rana D. Incebacak Eltemur,
  • Anna Würth,
  • Daniel Weishäupl,
  • Miriam Döcker,
  • Gunnar Blumenstock,
  • Sandra Martins,
  • Jorge Sequeiros,
  • Guy A. Rouleau,
  • Laura Bannach Jardim,
  • Maria-Luiza Saraiva-Pereira,
  • Marcondes C. França Jr.,
  • Carlos R. Gordon,
  • Roy Zaltzman,
  • Mario R. Cornejo-Olivas,
  • Bart P. C. van de Warrenburg,
  • Alexandra Durr,
  • Alexis Brice,
  • Peter Bauer,
  • Thomas Klockgether,
  • Ludger Schöls,
  • Olaf Riess,
  • Peter Bauer,
  • José Berciano,
  • Sylvia Boesch,
  • Alexis Brice,
  • Alexandra Durr,
  • Sylvie Forlani,
  • Paola Giunti,
  • Heike Jacobi,
  • Thomas Klockgether,
  • Bela Melegh,
  • Massimo Pandolfo,
  • Olaf Riess,
  • Tanja Schmitz-Hübsch,
  • Ludger Schöls,
  • Jörg B. Schulz,
  • Giovanni Stevanin,
  • Sandra Szymanski,
  • Sophie Tezenas du Montcel,
  • Dagmar Timmann,
  • Bart P. C. van de Warrenburg,
  • Thorsten Schmidt

摘要

Machado–Joseph disease (MJD) is an autosomal dominant neurodegenerative spinocerebellar ataxia caused by a polyglutamine-coding CAG repeat expansion in the ATXN3 gene. While the CAG length correlates negatively with the age at onset, it accounts for approximately 50% of its variability only. Despite larger efforts in identifying contributing genetic factors, candidate genes with a robust and plausible impact on the molecular pathogenesis of MJD are scarce. Therefore, we analysed missense single nucleotide polymorphism variants in the PRKN gene encoding the Parkinson's disease-associated E3 ubiquitin ligase parkin, which is a well-described interaction partner of the MJD protein ataxin-3, a deubiquitinase. By performing a correlation analysis in the to-date largest MJD cohort of more than 900 individuals, we identified the V380L variant as a relevant factor, decreasing the age at onset by 3 years in homozygous carriers. Functional analysis in an MJD cell model demonstrated that parkin V380L did not modulate soluble or aggregate levels of ataxin-3 but reduced the interaction of the two proteins. Moreover, the presence of parkin V380L interfered with the execution of mitophagy—the autophagic removal of surplus or damaged mitochondria—thereby compromising cell viability. In summary, we identified the V380L variant in parkin as a genetic modifier of MJD, with negative repercussions on its molecular pathogenesis and disease age at onset.